ZYTIGA^®
(abiraterone acetate)

About ZYTIGA^®1

ZYTIGA® is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with prednisone for the treatment of patients with:

• metastatic castration-resistant prostate cancer (CRPC)
• metastatic high-risk castration-sensitive prostate cancer (CSPC)

ZYTIGA® works by interrupting the androgen-making process at an important step. It inhibits androgen at 3 sources – the testes, adrenal glands, and the tumor itself. Other medications only decrease androgen production in the testes and do not affect the adrenal glands or prostate tumor tissue.

Why is Prednisone included with ZYTIGA^®?

To decrease the chance of certain side effects, you must take prednisone with ZYTIGA^® exactly as your healthcare provider tells you. Your healthcare provider will check your blood pressure, do blood tests to check your potassium levels, and check for any signs and symptoms of fluid retention every month during treatment with ZYTIGA^®. For more information, talk to your doctor.

Take your prednisone exactly how your healthcare provider tells you to. Do not stop taking your prescribed dose of ZYTIGA^® or prednisone without talking to your healthcare provider first.

For full prescribing information for ZYTIGA®, visit:

Zytiga.com